AbsoluteDx Breast Cancer
Use
AbsoluteDx Breast Cancer analyzes all clinically significant and actionable genes associated with breast cancer. It integrates with the Multi-Ancestry Breast Cancer PRS to assess risk in non-carriers and modulate the expected penetrance, offering a precise risk estimation for the individual tested.
Special Instructions
Test ordered through Allelica's secure platform. Provider can order the test directly and use collection kits in-clinic or for at-home sampling. Patient provides a simple, non-invasive saliva sample for DNA extraction, which is sent to Allelica’s CLIA, CAP laboratory.
Limitations
The test relies on accurate identification and integration of both monogenic mutations and polygenic risk. Risk estimates are modulated based on ancestry-specific PRS and are subject to the quality and accuracy of sequencing data and analytical models. Limitations can arise from reliance on large cohort data and assumptions in ancestry-specific calibrations.
Methodology
NGS (WGS)
Biomarkers
Result Turnaround Time
3-4 weeks
Related Documents
For more information, please review the documents below
Specimen
Saliva
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Patient provides a simple, non-invasive saliva sample for DNA extraction